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Abstract 12 
Hormone receptor-positive breast cancer is commonly treated with endocrine therapy; 13 
however, overtime cancer cells can develop endocrine resistance. This review aims to 14 
document combination therapy and sequential therapy in the use of endocrine agents and 15 
targeted agents. By conducting two systematic searches using 4 databases: Cochrane 16 
Library, MEDLINE, EMBASE, and Web of Science. A total of 26 studies that covered 17 
combination therapy were obtained and included for the review. 14 were phase III 18 
documenting combinations of mechanistic target of rapamycin (mTOR), phosphoinositide-3-19 
kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), human epidermal 20 
growth factor receptor 2 (HER2), and cyclin dependent kinase 4/6 (CDK4/6) inhibitors. The 21 
remaining studies were of phase II nature that reported combinations involving inhibitors in 22 
mTOR, endothelial growth factor receptor (EGFR), CDK4/6, and tyrosine kinase inhibitor 23 
(TKI). Interesting findings in inhibitor combinations involving; CDK4/6, mTOR and PI3K 24 
suggest clinical activity that can overcome endocrine resistance. On the other hand, there 25 
were 0 studies that covered sequential therapy. Overall findings showed that combination 26 
therapy improved treatment efficacy over monotherapy in postmenopausal patients with 27 
hormone-receptor positive advanced breast cancer. Inevitably, the benefits are 28 
accompanied with increased toxicity. To optimise endocrine therapy, further research into 29 
combinations and effective patient selection will need to be defined. Additionally, this 30 
review warrants future studies to explore sequential therapy. 31 
 32 
Introduction 33 
Endocrine therapy (ET) is often used as first line treatment in patients with hormone 34 
receptor positive (HR+) breast cancer and preferred to chemotherapy when there are no 35 
signs of visceral crisis (Reinert and Barrios 2015). In terms of efficacy, ET improves 36 
progression-free-survival (PFS), time to progression (TTP), objective response rate (ORR) and 37 
clinical benefit response (CBR), while possessing a favourable toxicity profile when 38 
compared to chemotherapy. Although, the therapeutic action of ET is slower than 39 
chemotherapy, the duration of response in ET is more sustainable with longer-term survival 40 
benefits (Cheung 2007). Recent data from the FALCON trial observed significant 41 
improvements in not just PFS and  TTP but also overall survival (OS) for postmenopausal 42 
patients with endocrine naïve, HR+ locally advanced/metastatic breast cancer (LABC/MBC) 43 
when treated with fulvestrant 500mg, as opposed to anastrozole 1mg (Robertson, et al. 44 
2016). All HR+ breast cancer can be represented with the presence of oestrogen receptor 45 
(ER) and/or progesterone receptor (PR) (Cheung 2007). The Americain Soceity of Clinical 46 
Oncology/College of American Pathologists recommended HR+ tumours be defined as 47 
having at least 1% of tumour nuclei stained positively for either ER or PR on 48 
immunohistochemistry (Hammond, et al. 2010). Unfortunately, patients with ER+ breast 49 
cancer are susceptible to risks of progressive disease (PD) or develop endocrine resistance 50 
(Dixon 2014). As a result, investigations in modalities of ET agents have been thorough and 51 
produced a wide-range of ET options for patients to use. 52 
A greater understanding in cancer biology has shown that ESR1 mutation is associated with 53 
mechanisms of endocrine resistance, especially to tamoxifen and fulvestrant (Jeselsohn, et 54 
al. 2015). About 15-20% of ER+ LABC/MBC were shown to have ESR1 mutation, with 55 
increased frequencies detected in patients with multiple ET exposure. Research into 56 
biochemical pathways associated with proliferation has identified that cross-talk between 57 
signalling pathways can activate ERs, despite conventional ER pathways being blocked or 58 
inactivated (Dixon 2014; Pietras 2006). For instance, cross-talk between ER and specific 59 
pathways such as the phosphoinositide 3-kinase /v-akt murine thymoma viral oncogene 60 
/mammalian target of rapamycin (PI3K/AKT/mTOR) can result in continued proliferation of 61 
the cancer cells and hence develop resistance to ET (Dixon 2014). Targeted therapy agents 62 
(TA) are designed to interfere with specific targets that are involved with growth. Often TA 63 
act on specific molecular targets to achieve blockade of cell proliferation and potential 64 
cross-talks between the ER mediated pathway and other signalling pathways. Most TA are 65 
categorised by their molecular target (see Table 1). Accordingly, the concomitant use of TA 66 
with other cancer therapeutics can potentially further increase treatment efficacy and 67 
overcome endocrine resistance (Pietras 2006). However, combination therapy is prone to a 68 
greater toxicity profile when compared to monotherapy. Hence, an alternative would be the 69 
sequential application of ET and TA, which is expected to lessen the toxicity profile of these 70 
regimen. In sequential therapy, the patient will be exposed to only one toxicity profile at 71 
once rather than two during combination therapy.  From figure 1, it was of interest if 72 
sequential application of an ET agent (blue) and TA (red) will produce similar efficacy when 73 
compared to combination therapy (green). Another interesting comparison of these 74 
treatments would be to compare the results of different sequencing pattern in sequential 75 
ET (in this case treatment B and C). Henceforth, this was the definition of combination 76 
therapy and sequential therapy in this review.  77 
An ever-growing arsenal of anticancer agents requires knowledge in optimal application for 78 
clinicians and patients to make informed decisions regarding therapeutic strategies. The aim 79 
was to assimilate methodologies and conclusions of randomised control trials (RCTs) 80 
investigating the benefits/limitations of combination and sequential therapy of ET/TA. 81 
 82 
Methods 83 
This systematic review was conducted by electronic searches to include relevant phase II/III 84 
RCTs that have reviewed the application of ET and TA in combination therapy or sequential 85 
therapy. Relevant literatures were screened for their title, followed by evaluation of 86 
abstracts befitting the selection criteria. Lastly, availability of full articles and abstracts in 87 
eligible literature were reviewed. Two separate searches were performed in parallel to 88 
accommodate the aims of the review. 89 
A comprehensive search was performed with multiple databases: Medline, EMBASE, 90 
Cochrane Library and Web of Science. Both searches included ‘endocrine therapy’, 91 
‘hormone’, ‘advanced breast cancer’, ‘metastatic’ and ‘postmenopausal’. Additional search 92 
terms: ‘combination’, ‘plus’, ‘add’ and ‘together’ were incorporated into the search for 93 
combination therapy. Whereas, search terms: ‘sequential’, ‘switch’, ‘concurrent’, and 94 
‘concomitant’ were included for the sequential therapy search. Cross-referencing of 95 
relevant literature was also conducted to expand the literature search. Conference abstracts 96 
were also considered for screening, to include on-going studies for review. The search was 97 
limited to English language and RCTs that investigated combinations or sequential 98 
applications of ET and TA in postmenopausal patients with HR+ advanced/metastatic breast 99 
cancer in phase II/III. The search was carried out from 1998 onwards, because trastuzumab 100 
was approved by the Food and Drug Administration on this year (Roche and Ingle 1999). The 101 
Critical Appraisal Skill Programme (CASP) RCT checklist was used for critical appraisal of 102 
founded studies.  103 
 104 
Inclusion criteria 105 
 ET combination with TA  106 
 Sequential use of ET with TA 107 
 Primary interest of ET agents includes: 108 
o Selective Oestrogen Receptor Modulators (SERMs): tamoxifen 109 
o Steroidal third-generation Aromatase Inhibitors (AIs): exemestane 110 
o Non-steroidal third-generation AIs: anastrozole or letrozole 111 
o Selective Oestrogen Receptor Downregulators (SERDs): fulvestrant 112 
 Study title must be a RCT that report any of the following molecular TA with ET: 113 
o HER2 inhibitors 114 
o mTOR inhibitors 115 
o CDK4/6 inhibitors 116 
o VEGFR inhibitors  117 
o EGFR inhibitors 118 
o PI3K inhibitors 119 
o TKIs  120 
 Study must offer full text or abstract that provide details in:  121 
o Background/Introduction 122 
o Methods 123 
o Results 124 
o Discussion/Conclusion 125 
 HR+ breast cancer may include: 126 
o ER+, PR+, HER2+ 127 
o ER+, PR+, HER2- 128 
o ER+, PR-, HER2- 129 
o ER+, PR-, HER2+ 130 
o ER-, PR+, HER2+ 131 
o ER-, PR+, HER2- 132 
 Study must recruit postmenopausal patients or in addition to premenopausal patients  133 
 Prior chemotherapy was acceptable in abstract screening of RCTs  134 
 135 
Exclusion criteria 136 
 Keywords “chemotherapy” or “radiotherapy” stated in title or in combination with ET 137 
 Combination of ET agents (SERDs, AIs, SERMs) 138 
 “Premenopausal” or “Early breast cancer” stated in title   139 
 Study solely on premenopausal patients  140 
 Non-human studies 141 
 Neo-adjuvant studies  142 
 143 
Primary outcome 144 
The primary objective was to evaluate the effectiveness of combination therapy and 145 
sequential therapy in optimising ET. The optimisation of ET will be measured by observed 146 
improvements in PFS, ORR, TTP, CBR and overall survival (OS). Remarks of overcoming 147 
endocrine resistant will also be considered. 148 
 149 
Secondary outcome 150 
The benefits and limitations of combination therapy and sequential therapy were evaluated. 151 
Parameters included: quality of life (QoL), toxicity and cost-effectiveness will also be 152 
considered.  153 
It was hypothesised that combination therapy was a more suitable option to optimising ET 154 
when compared to sequential therapy in terms of improving treatment efficacy and 155 
overcoming endocrine resistance.  156 
 157 
Results 158 
Combination therapy search 159 
From Figure 2, an initial detection of 2866 articles from the 4 databases. A final total of 26 160 
studies was achieved, after removal of duplicates, title and abstract screening according to 161 
the inclusion and exclusion criteria stated in methods.  162 
 163 
From Table 2, there are 9 studies addressing ET/mTOR, 3 ET and CDK4/6, 1 study addressing 164 
ET/PI3K, 3 studies addressing ET/HER2, 2 studies addressing ET/VEGFR, 5 studies addressing 165 
ET/EGFR, and 3 studies addressing ET/TKI combinations. 2 studies had CBR as their primary 166 
endpoint and the rest of the studies had PFS.  167 
 168 
ET combinations with mTOR inhibitors (phase III/II) 169 
The combination of exemestane and everolimus was well documented in the international, 170 
phase 3, multicentre, randomised, double-blind, placebo-controlled trial: BOLERO-2 171 
(Baselga, et al. 2012; Burris, et al. 2013a; Burris, et al. 2013b; Piccart, et al. 2012; Yardley, et 172 
al. 2013). The targeted population consisted of postmenopausal women with HR+, HER2- 173 
locally ABC or MBC whom experienced PD from letrozole or anastrozole. Eligible patients 174 
were randomised in a blind manner at a 2:1 ratio for the experimental arm (25mg/day 175 
exemestane and 10mg/day oral everolimus) or matching placebo. The investigation in 176 
BOLERO-2 showed significant improvements in PFS and other efficacy parameters (see Table 177 
8). These improvements in efficacy were also maintained in patients with visceral disease, 178 
elderly and of Asian ethnicity. Thus, the everolimus/exemestane combination represents an 179 
improvement in managing a wider population of postmenopausal women with HR+, HER2-180 
ABC. Furthermore, BOLERO-2 is the only study that reported QoL. Burris et al. reported 181 
similar baseline global health status score in treatment and placebo regimen (64.7 vs 65.3) 182 
(Burris et al. 2013b). The similar outcome of QoL further supports the use of everolimus 183 
with ET. 184 
Despite BOLERO-2 advocated the benefits of using mTOR inhibitor, contrasting finding in PFS 185 
was observed in the HORIZON study (Wolff, et al. 2013). This study involved investigation in 186 
the use of letrozole in combination with the oral mTOR inhibitor temsirolimus. This 187 
combination failed to improve PFS (8.9 vs 9.0 months), ORR (27% vs 27%) and OS. Moreover, 188 
a raised toxicity profile in the combination arm resulted in more grade 3/4 AEs (37% vs 24%). 189 
However, it was speculated that the contrasting findings in both trials were due to key 190 
differences in eligible patient characteristics (Wolff et al. 2013). For instance, HORIZON 191 
excluded patients with prior AI exposure within 12 months, whereas eligible patients in 192 
BOLERO-2 required progression from a non-steroidal AI during or within 12 months. This 193 
speculation highlights the significance of patient selection to determining the success of the 194 
treatment regimen. Interestingly, it was noted in the HORIZON study observed an improved 195 
PFS (9.0 vs 5.6 months) limited to patients aged 65 treated with the combination 196 
letrozole/temsirolimus rather than in patients aged 65 (8.5 vs 10.1 months). This finding 197 
suggests that temsirolimus activity may favour the younger population over the older 198 
population (Wolff et al. 2013). Again, this proposal accentuates the importance of patient 199 
selection for treatment success.  200 
From the open-labelled RCT (TAMRAD) that investigated the tamoxifen/everolimus 201 
combination. An interesting finding in CBR suggested possible reversal of ET resistance and 202 
subsequent improvements. Overall CBR at 6 months was 61% vs 42%. Moreover, 203 
improvements in CBR were consistent in patients with secondary resistance (74% vs 48%) 204 
and in patients with primary resistance (46% vs 38%). Similar findings in TTP (14.8 vs 5.5 205 
months) was more prominent in patients with secondary resistance as oppose to those with 206 
primary resistance (5.4 vs 3.8 months) (Bachelot, et al. 2012). Therefore, this combination 207 
may benefit patients with AI-resistance MBC. However, this trial was relatively small with a 208 
total of 111 patients and may be prone to bias. Small imbalances between groups’ 209 
performance status were notable (Bachelot et al. 2012). Hence this study was confirmed 210 
only for hypothesis generating and warrant further study into this area (Bachelot et al. 211 
2012).  212 
 213 
ET combinations with CDK4/6 inhibitor (phase III/II) 214 
Positive results were observed when novel CDK4/6 inhibitor palbociclib was added to ET. 215 
From table 3, PALOMA-2 (letrozole/palbociclib) and PALOMA-3 (fulvestrant/palbociclib) 216 
have shown improvements in efficacy parameters. In both PALOMA-2 and PALOMA-3, 217 
significant improvements in PFS, ORR and CBR were reported. In terms of toxicity, 218 
neutropenia (79.5% vs 6.3%) was evident when palbociclib was added. Nonetheless, 219 
PALOMA-2 confirmed the significant clinical benefits and safety of using 220 
palbociclib/letrozole to treat postmenopausal patients whom had no prior systemic therapy 221 
for their ER+, HER2- ABC (Finn, et al. 2016a; Finn, et al. 2016b). 222 
From PALOMA-3, patients with HR+, HER2- MBC were randomised in a double-blind manner 223 
to fulvestrant (500mg, intramuscular injections on days 1 and 15 of cycle one and then on 224 
day 1 of each 28-day cycle) and palbociclib or placebo (125mg/day oral for 3 weeks, 225 
followed by 1 week off in a 28-day cycle). Although, this trial recruited both pre- and 226 
postmenopausal women, premenopausal women were treated with goserelin (LHRH 227 
agonist) to induce postmenopausal status. Significant improvements in PFS (9.5 vs 4.6 228 
months), ORR (66% vs 15%) and CBR (67% vs 40%) were observed. The benefits of 229 
palbociclib/fulvestrant in PFS compared to fulvestrant/placebo were consistent irrespective 230 
of the degree of HR expression, PIK3CA mutation, ET resistance and ethnicity. These findings 231 
propose the possibility of re-sensitising endocrine sensitivity in ET resistant tumours by 232 
targeting of CDK4/6. Common toxicities include: neutropenia, leukopenia, fatigue and 233 
anaemia were observed in ET/palbociclib arms. These haematological changes should be 234 
considered during patient selection for this therapeutic strategy. Endocrine monotherapy 235 
had limited efficacy in patients with PD from prior ET, proposing a need for further 236 
investigations into the effective use of combination regimens to overcome this problem 237 
(Cristofanilli, et al. 2016).  238 
 239 
ET combinations with PI3K inhibitors (phase III) 240 
BELLE-2 was a randomised, double-blinded, placebo-controlled phase III trial that 241 
investigated the addition of buparlisib to fulvestrant. Overall promising results were 242 
observed; with PFS, ORR and CBR all being improved in the experimental arm. The toxicity 243 
profile of the addition of buparlisib seems to be associated with liver function; with increase 244 
in alanine aminotransferase (26% vs 1% and aspartate aminotransferase (18% vs 3%). 245 
Hence, the use of buparlisib in patients with poor liver function should be cautioned. 246 
Interestingly, Baselga J et al. reported that buparlisib significantly improved median PFS, 247 
ORR and CBR in patients with PIK3CA mutant ctDNA but the same activity was not observed 248 
in patients without the mutation. Furthermore, patients characterised with PIK3 mutated 249 
tumours are associated with endocrine-resistant HR+, HER2- ABC (Baselga, et al. 2016). This 250 
proposes the possibility that the targeting of PI3K pathway may be an area to explore for 251 
overcoming endocrine resistance.  252 
 253 
ET combinations with HER2 inhibitors (phase III) 254 
Positive results of adding HER2 inhibitor to ET was shown in the TAnDEM study 255 
(anastrozole/trastuzumab) and in a phase III study that investigated letrozole in 256 
combination with lapatinib (Burstein, et al. 2014; Johnston, et al. 2009; Kaufman, et al. 257 
2009). PFS and CBR were greatly enhanced, with a doubling of PFS was seen in both studies 258 
(see Table 3). However, the increase in PFS did not correlate with OS. More AEs were 259 
reported in the combination arm in both studies. Moreover, an increase in cardiac events 260 
(14 vs 2) was observed in anastrozole/trastuzumab when compared to anastrozole alone. 261 
Johnston et al. also discussed the problem of ET resistance in HR+, HER2+ breast cancer and 262 
concluded that the addition of lapatinib did not delay disease progression with letrozole in 263 
endocrine-sensitive tumours. In general, the studies concur that addition of HER2 inhibitors 264 
to ET in HR+, HER2+ breast cancer can prolong chemoprevention and increase ET efficacy.  265 
CALGB 40302 was a randomised, double-blinded, placebo-controlled phase III study that 266 
investigated the fulvestrant/lapatinib combination. Conversely, there was a lack of 267 
improvement in clinical outcomes. Though, it was noted that PFS was improved in patients 268 
with HER2+ tumours (5.9 vs 3.3 months) as oppose to HER2- tumours (4.1 vs 3.8 months) 269 
when lapatinib was added. However, this study had a small number of HER2+ cases (18%) 270 
with the majority being HER2- tumours (81%). Hence, this could be a limitation of the study 271 
that patient recruitment could have been amended to include more HER2+ cases to 272 
maximise activity of the HER2 inhibitor. Although the experimental regimen was generally 273 
tolerable, there were more AEs and treatment discontinuation caused from the raised 274 
toxicity. Overall, CALGB 40302 concluded that lapatinib did not significantly improve clinical 275 
benefits when added to fulvestrant (Burstein et al. 2014).  276 
 277 
ET combinations with VEGFR inhibitor (phase III) 278 
From table 3, the CALGB 40503 (letrozole with bevacizumab) and LEA study 279 
(letrozole/fulvestrant with bevacizumab), reported of contrasting findings in PFS. According 280 
to the CALGB 40503 study, the addition of bevacizumab to letrozole improved PFS (20.2 vs 281 
15.6 months) when compared to the placebo arm. Moreover, ORR (69% vs 49%) and CBR 282 
(80% vs 62%) exhibited similar improvements from the addition of bevacizumab. However, 283 
the significant improvement in PFS, ORR and CBR did not correlate with OS (47.2 vs 43.9 284 
months) (Dickler, et al. 2016). Similar improvements in PFS (19.3 vs 14.4 months), ORR (41% 285 
vs 22%) and CBR (77% vs 66%) were observed in the LEA study. However, the difference in 286 
PFS was not statistically significant: the hazard ratio of the combination arm vs ET alone was 287 
0.83 (p=0.126) (Martin, et al. 2015). Unsurprisingly, bevacizumab combinations were 288 
associated with increased AEs; mainly hypertension and proteinuria. The LEA study reported 289 
of deaths in the bevacizumab arm that seem to be associated with conditions that may have 290 
been worsened from the hypertensive side-effects (Martin et al. 2015). As a result, patients 291 
with hypertensive conditions should avoid the use of bevacizumab.  292 
One of the limitations of the LEA study was the lack of comparison of letrozole and 293 
fulvestrant when in combination with bevacizumab. All the data assimilated was grouped 294 
together either as ET/bevacizumab and ET alone. Further sub-groups within 295 
ET/bevacizumab to compare letrozole/bevacizumab and fulvestrant/bevacizumab would 296 
have provided more information on optimal application of bevacizumab to ET. 297 
 298 
ET combinations with EGFR inhibitor (phase II) 299 
Marked advantage in PFS was reported when gefitinib was added to anastrozole in 300 
comparison to placebo (see Table 4) (Cristofanilli, et al. 2010; Valero, et al. 2009). 301 
Improvement in PFS was also observed in the study of tamoxifen in combination with 302 
gefitinib. For this trial, patients were split into two groups: stratum 1 (PD after tamoxifen) 303 
and 2 (PD during/after AI). PFS was only improved in stratum 1 (10.9 vs 8.8 months), but not 304 
in stratum 2 (5.7 vs 7.0 months). The significant improvement of PFS in stratum 1 suggests 305 
possible endocrine re-sensitisation when gefitinib was added to an ET (tamoxifen, in this 306 
case) that was previously used (Osborne, et al. 2011). A sub-analysis of PFS in patients with 307 
prior ET therapies (11.2 vs 7.1 months) and ET naïve (20.2 vs 8.4 months) was observed 308 
using gefitnib/anastrozle vs placebo arm (Cristofanilli et al. 2010). These findings suggest a 309 
potential role of overcoming ET resistance from using gefitinib. On the other hand, 310 
Tryfonidis et al. argued that the toxicity profile (mainly skin and gastrointestinal related) of 311 
gefitinib resulted in premature therapy interruption in 33% of patients. Additionally, the PFS 312 
rate at 1 year was only 35% for combination arm and 32% for placebo arm (Tryfonidis, et al. 313 
2016). Hence, the use of gefitinib was not supported in a risk/benefit point of view. Carlson 314 
et al. echoed similar opinion in further trials of combinations of gefitnib with 315 
anastrozole/fulvestrant, despite modest findings in anti-tumour activities (Carlson, et al. 316 
2012). Overall PFS comparison seemed similar (5.3 vs 5.2 months in anastrozole and 317 
fulvestrant arms respectively) but in patients who had prior chemotherapy, a significant 318 
deterioration in PFS was seen in the fulvestrant/gefitinib arm (2.6 months) (Tryfonidis et al. 319 
2016). Although it was unexplained why these changed were observed, it can be inferred 320 
that prior treatment can have an impact on future treatments. 321 
 322 
ET combinations with TKI (phase II) 323 
The general consensus toward TKI/ET combinations seem negative. Johnston et al. reported 324 
a 3 arms trial of anastrozole (1mg/day) in combination with AZD8931 at 20mg (twice daily), 325 
40mg (twice daily) or placebo. Although PFS (13.8 vs 14.9 vs 10.9 months) was increased, it 326 
was statistically insignificant (see Table 4) (Johnston, et al. 2016). This therapeutic strategy 327 
does not seem to enhance ET responsiveness and was generally associated with a greater 328 
toxicity profile when compared to ET alone. Wright et al. reported that the addition of 329 
dasatinib to fulvestrant did not improve PFS (6.0 months vs 5.3 months), CBR and OS. In 330 
fact, CBR (28.0% vs 32.7%) and OS (17.0 vs 21.7 months) seemed to worsen with 331 
dasatinib/fulvestrant when compared to placebo (Wright, et al. 2011). This may suggest that 332 
a worse safety profile and patient tolerability could potentially influence the patient’s QoL 333 
and ultimately OS. Finally, in the fulvestrant/dovitinib study, an improvement in PFS (10.9 vs 334 
5.5 months) was observed. Though only limited to patients with FGF pathway-amplified 335 
breast cancer in fulvestrant/dovitinib vs placebo arm respectively. Contrastingly, patients 336 
without FGF-pathway-amplification gained no effect from the addition of dovitinib (5.5 vs 337 
5.5 months), other than the increased toxicity associated in combination therapy (Musolino, 338 
et al. 2017). This discovery highlights the importance of patient selection by identifying 339 
cancer biology to maximise treatment prognosis.  340 
 341 
Sequential therapy search 342 
From figure 3, an initial detection of 901 articles. A final total of 0 studies was identified, 343 
after removal of duplicates, title and abstract screening according to the inclusion and 344 
exclusion criteria stated in methods. Therefore, the search for relevant literature in the 345 
sequential application of ET and TA was unsuccessful.  346 
 347 
Discussion  348 
This review aimed to explore options for the optimisation of ET with TA by methods of 349 
combination therapy or sequential therapy. From assimilating relevant studies, it was clear 350 
that combination therapy is investigated more thoroughly than sequential therapy. The 351 
identification of benefits and limitations in both combination and sequential therapy was 352 
not met due to the absence of literature available in sequential therapy. The result of 0 353 
articles warrants the need of future investigation in this area.   354 
It was hypothesised that combination therapy would be the better option in optimising ET. 355 
Most combinations of ET and TA have yielded extremely promising results, notably in 356 
enhancing treatment efficacy (PFS, ORR and CBR). The classes of TA reviewed in this 357 
systematic review included: mTOR inhibitors, EGFR inhibitors, TKI, CDK4/6 inhibitors, VEGFR 358 
inhibitors, PI3K inhibitor, and HER2 inhibitors. Most treatment combinations were effective 359 
in treating patients with HR+, HER2- ABC/MBC. Evidently, the best combination arms 360 
included CDK4/6 inhibitor, PI3K inhibitor and mTOR inhibitors in treating this population. 361 
These combinations seem to optimise ET by producing significant improvements in PFS, CBR 362 
and ORR, regardless of patients’ treatment history and overcoming endocrine resistant. The 363 
additional benefits from combination therapy were associated with an increase in toxicity. 364 
This was a common trend in all included studies. Consequently, combination therapy may 365 
prove difficult in patients whom do not tolerate these regimens, for instance in the elderly 366 
population.  367 
All studies documented the toxicity profile of the combination against the comparison arm. 368 
However, it was unknown how these toxicities may have impacted the patient being 369 
treated. Most studies had stated that one of the main reasons for patient discontinuation 370 
was related to treatment toxicity. Data in these areas should identify treatment tolerability, 371 
patients’ QoL and financial feasibility for sustainable treatment. Therefore, clinicians will be 372 
provided with a better understanding on the ideal application of ET and TA. 373 
Throughout the review, it was evident that some combinations (TKI, EGFR and VEGFR) failed 374 
to produce any benefits over ET alone. Differences in study design seemed to be the most 375 
likely explanation for contrasting findings in RCTs with similar experimental arms. Most RCTs 376 
used methods such as: double-blinding, placebo-controlled, and 2-arm trial. Although some 377 
RCTs deviated from this and employed an open-label approach and the absent of placebo. 378 
Hence those RCTs may be of lower power than those that used the double-blinding and 379 
placebo-control methods to minimise chances of bias. 380 
 381 
Patient selection 382 
It was implied that the importance of patient selection seemed to influence treatment 383 
prognosis. From assimilating relevant study findings, this review suggests that patient 384 
selection can be categorised into 3 main areas: patient characteristics, cancer biology and 385 
pharmacology.  386 
 387 
Patient Characteristics: 388 
Patient characteristics such as age have shown to influence drug efficacy. In the HORIZON 389 
study, temsirolimus produced PFS benefits in younger patients as opposed to older patients 390 
(Wolff et al. 2013). Thus, the use of SERMs and SERDs in combination to temsirolimus may 391 
exhibit greater benefit in selected younger patients than using AIs which are restricted to 392 
the postmenopausal population. However, it should be reminded that not all 393 
postmenopausal patients are of the older population. Younger patients can obtain the 394 
postmenopausal status via oophorectomy or the use of a luteinising hormone releasing 395 
hormone agonist. Another aspect to consider in older patients would be treatment 396 
tolerability. From the LEA study, details of patients’ deaths were reported in the 397 
bevacizumab arm (n=8) (Martin et al. 2015). Some deaths were associated with conditions 398 
that may have been exacerbated from the hypertensive side effects. Further inspection, 399 
revealed that the patient age ranged from 53-82 years old and 5 out of 8 patients had 400 
hypertension as baseline co-morbidity (Martin et al. 2015). Therefore, specific co-401 
morbidities in individual patients should be considered when selecting regimens. As 402 
evidently different classes of TA are associated with specific toxicities: palbociclib 403 
(neutropenia), bevacizumab (hypertension), trastuzumab (cardiac events), and EGFR 404 
inhibitors (skin and gastrointestinal). 405 
 406 
Cancer Biology: 407 
The identification of specific targets can broaden the options for therapeutic strategies. For 408 
instance, the use of dovitinib (TKI that inhibits FGF pathways) in combination with 409 
fulvestrant was shown to significantly improve PFS in patients with FGF pathway-amplified 410 
breast cancer (10.9 vs 5.5 months) when compared to the placebo arm. Whereas, patients 411 
without FGF pathway amplification did not benefit from the dovitinib/fulvestrant  412 
combination (5.5 vs 5.5 months) (Musolino et al. 2017). Burstein et al. also reported greater 413 
improvement in PFS and ORR, when the HER2 inhibitor lapatinib was added to fulvestrant in 414 
patients with HER2+ status than in those with HER2- (Burstein et al. 2014). These findings 415 
support the importance of patient selection, by identifying cancer biology to maximise 416 
treatment success.  417 
 418 
Pharmacology: 419 
Pharmacology was another factor that should be considered during patient selection for 420 
suitable therapeutic strategy. It was clear from the findings in this systematic review, that 421 
prior therapy can influence treatment prognosis. This was evident in studies of ET/EGFR 422 
combinations, whereby prior ET or chemotherapy had caused dramatic changes in 423 
treatment outcome. In the phase II study that investigated the anastrozle/gefitinib 424 
combination, Cristofanilli et al. reported an exploratory post hoc subset analysis of patients 425 
with endocrine naïve and prior ET. An all-round improvement in PFS was observed in both 426 
subset. But, the data seem to suggest superior benefits in PFS for patients with endocrine 427 
naïve (20.2 months) in contrast to patients who had prior ET (11.2 months) (Cristofanilli et 428 
al. 2016). From these findings, it was confirmed that endocrine monotherapy had limited 429 
efficacy in patients with PD from prior ET, proposing a need for further investigations into 430 
the effective selection of combination regimens to overcome this problem. Furthermore, 431 
this proposes that the use of combination therapy in a first line setting may benefit those 432 
with naïve treatment. Although, some combinations (CDK4/6, PI3K, EGFR, and mTOR) have 433 
shown activity to overcome ET resistance in patients with prior ET exposure. Yet it was 434 
unspecified if the number of prior therapies may further diminish the outcome in 435 
combination therapy. Hence this may be another area to be for future investigations. 436 
 437 
Overcoming resistant: 438 
One of the criteria for optimising ET in this review was to overcome ET resistance. This 439 
question was met in findings from phase III PALOMA-3 and BELLE-2 studies suggesting that 440 
targeting CDK4/6 and PI3K hold the most promise. This was supported by in vitro evidence 441 
suggesting cancer cells that have developed ET resistance remain dependent on cyclin D1 442 
and CDK4 for proliferation. Similarly, pre-clinical evidence has identified a potential cause of 443 
endocrine resistance via cross-talk between ER and PI3K pathways (Milani, et al. 2014). 444 
Additional findings from phase II ET combinations with gefitinib and everolimus suggested 445 
signs of delaying ET resistance or re-sensitising tumours with ET resistance promise 446 
(Bachelot et al. 2012; Tryfonidis et al. 2016). This prompts further research into overcoming 447 
ET resistance by targeting these pathways.  448 
 449 
Sequential application 450 
There was evidently a lack of knowledge about the sequential application of ET and TA. This 451 
review has identified areas that combination therapy has failed to impress and a new 452 
approach in optimal application of specific target agents was needed. For instance, the 453 
activity of gefitinib with ET has suggested effects of delaying ET resistance. But in a 454 
combination setting, the regimen seemed to only increase toxicity while retaining similar 455 
efficacy seen in endocrine monotherapy (Tryfonidis et al. 2016). Hence the sequential 456 
application of these agents could be a feasible alternative. A predicted decrease in toxicity 457 
would provide a more tolerable profile for patients. This will be important for management 458 
of the elderly population where tolerability may be an issue. Classes of TA such as TKIs, 459 
VEGFR inhibitors and HER2 inhibitors when in combination created unfavourable tolerability 460 
in patients. Therefore, those classes of agents may benefit from this sequential approach.  461 
 462 
Limitations  463 
The term “targeted agents” was narrowly defined to fit the feasibility of generating this 464 
systematic review. Several agents were excluded from this review included: proteasome 465 
inhibitors and farnesyltransferase inhibitors. Moreover, combination therapy was strictly 466 
defined to only include 2 agent combinations and excluding studies that have explored the 467 
feasibility of more than 2 agent combinations such as triple combinations. Thus, this review 468 
does not reflect the true potential depth of combination therapy and diversity of TA 469 
available for optimising ET.  470 
The method in selecting papers was rigorously determined by the presence of specific 471 
keywords. Studies that were excluded solely based on title alone, may have contained 472 
relevant information in the abstract or within the full text. Thus, there was the possibility 473 
that relevant studies were missed.  474 
Furthermore, many trial status were “on-going” or “results pending”, this resulted in a 475 
narrow range of agents being incorporated into this review. This was especially evident in 476 
the attempt of including novel agents that targeted the PI3K pathway. Consequently, the 477 
protocol was amended to allow inclusion of abstracts to generate a wider pool of agents 478 
and subsequent findings. However, limited information was provided in the abstracts when 479 
compared to full text. This was evident during analysis of study design and results.  480 
 481 
Conclusion 482 
Combination of ET and TA have proven to be effective at improving treatment efficacy over 483 
monotherapy in postmenopausal patients with HR+ ABC/MBC. However, not all 484 
combinations are adding benefit to ET and some are only increasing the toxicity profile. 485 
Indisputably, tolerability of toxicity in combination therapy of the elderly population possess 486 
an issue in patient management. As a result, this may be an opportunity for sequential 487 
therapy of ET and TA to be explored in this specific population.  488 
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 644 
Table/Figure Legends: 645 
Table 1. Some targeted therapy agents that have been used in treating breast cancer in 646 
combination with other forms of cancer treatment. 647 
Table 2. Summary of included phase II/III studies that address combination of ET and TA 648 
(mTOR inhibitors; CDK4/6 inhibitors; PI3K inhibitor; HER2 inhibitors; VEGFR inhibitor; EGFR 649 
inhibitor and TKI). Figures with * and ** represent figures from the same study. 650 
Table 3. Summarised findings of different parameters from each phase III studies. The table 651 
is formatted as followed: (experimental arm vs comparative arm). Regarding toxicities 652 
column, selected toxicity was chosen by availability from study and prevalence. 653 
* The changing of unit will be stated in the cell 654 
ctDNA = circulating tumour DNA 655 
Hr = Hazard ratio 656 
OR = Odd ratio 657 
p = p-value 658 
Table 4. Summarised findings in different parameters from each phase II studies. The table is 659 
formatted as followed: (experimental arm vs comparative arm). Regarding toxicities 660 
column, selected toxicity was chosen by availability from study and prevalence.  661 
* change of unit will be stated in the cell 662 
Hr = Hazard ratio 663 
OR = Odds ratio 664 
p = p-value 665 
 666 
Figure 1. A hypothetical comparison of combination therapy (Treatment A) and sequential 667 
therapy (Treatment B and C).  668 
ET = Endocrine therapy agent 669 
TA = Targeted agent 670 
ET/TA = Combination of endocrine therapy agent and targeted agent 671 
Blocked arrow = Duration of effective treatment from ET/TA 672 
Dashed arrow = Duration of effective treatment from ET 673 
Straight arrow = Duration of effective treatment from TA 674 
Figure 2. A flow diagram displaying the study selection process that addressed for 675 
combinations of ET with targeted agents adapted from PRISMA (Moher, et al. 2009) 676 
Figure 3. A flow diagram displaying the study selection process that addressed for sequential 677 
use of ET with targeted agents adapted from PRISMA (Moher et al. 2009) 678 
